AR067937A1 - Derivados de indol -2- ona disustituidos en 3, su preparacion y su aplicacion en terapeutica - Google Patents
Derivados de indol -2- ona disustituidos en 3, su preparacion y su aplicacion en terapeuticaInfo
- Publication number
- AR067937A1 AR067937A1 ARP080103547A ARP080103547A AR067937A1 AR 067937 A1 AR067937 A1 AR 067937A1 AR P080103547 A ARP080103547 A AR P080103547A AR P080103547 A ARP080103547 A AR P080103547A AR 067937 A1 AR067937 A1 AR 067937A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- alkyl
- group
- perhalogenoalkyl
- alkoxy
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000027559 Appetite disease Diseases 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
El procedimiento de preparacion, intermediarios y la aplicacion terapéutica de dichos compuestos en obesidad, diabetes, trastornos del apetito y sobrecarga ponderal. Reivindicacion 1: Compuesto que responde a la formula (1): en la que ---- representa un enlace sencillo o doble, X representa -NN- o >CH-, entendiéndose que al menos uno de X, Y representa N; Ar representa un grupo arilo o heteroarilo sustituido opcionalmente con uno o varios sustituyentes, idénticos o diferentes, elegidos entre los átomos de halogeno, los grupos alquilo C1-6, halogenoalquilo C1-6, perhalogenoalquilo C1-3, alcoxi C1-6, perhalogenoalcoxi C1-3, arilo; R1 representa un átomo de hidrogeno o un grupo alquilo C1-6, -C(=O)alquilo C1-6, -C(=O)arilo; R2, R3, R4, idénticos o diferentes, situados en una cualquiera de las posiciones disponibles del nucleo fenilo, representan independientemente un átomo de hidrogeno, un átomo de halogeno, CN , OH, un grupo alquilo C1-6 sustituido opcionalmente con un átomo de halogeno o un OH; perhalogenoalquilo C1-3, alcoxi C1-6, perhalogenoalcoxi C1-3, aminocarbonilo, alquil C1-6-aminocarbonilo, dialquil C1-6-aminocarbonilo, arilo, ariloxi; heteroarilo; pudiendo estar el grupo arilo, ariloxi o heteroarilo sustituido opcionalmente con un átomo de halogeno, CN, OH o un grupo alquilo C1-6, perhalogenoalquilo C1-3 o alcoxi C1-6; entendiéndose que al menos uno de R2, R3, R4 es diferente de H y que el grupo arilo, ariloxi o heteroarilo puede estar sustituido opcionalmente con un átomo de halogeno, CN, OH o un grupo alquilo C1-6, perhalogenoalquilo C1-3, alcoxi C1-6; R5 representa un grupo alquilo C1-6 o un alquenilo C2-6; y n representa 1 o2, en forma de base o de sal de adicion a un ácido; con la excepcion de 5-cloro-3-(2-clorofenil)-1,3-dihidro-3-[2-(4-metilpiperacin-1-il)acetamido]indol-2-ona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0705858A FR2920023B1 (fr) | 2007-08-16 | 2007-08-16 | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067937A1 true AR067937A1 (es) | 2009-10-28 |
Family
ID=39197313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103547A AR067937A1 (es) | 2007-08-16 | 2008-08-14 | Derivados de indol -2- ona disustituidos en 3, su preparacion y su aplicacion en terapeutica |
Country Status (42)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| FR2941946B1 (fr) | 2009-02-12 | 2011-03-25 | Sanofi Aventis | Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique |
| FR2941947B1 (fr) * | 2009-02-12 | 2011-03-25 | Sanofi Aventis | Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique |
| MY160123A (en) | 2009-02-13 | 2017-02-28 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| CN108658836B (zh) * | 2018-05-15 | 2021-04-20 | 宁波大学 | 一种3-取代-3-叠氮基吲哚-2-酮类化合物的制备方法 |
| EP3912625A1 (en) * | 2020-05-20 | 2021-11-24 | Kaerus Bioscience Limited | Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2714378B1 (fr) * | 1993-12-24 | 1996-03-15 | Sanofi Sa | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
| ES2237135T3 (es) * | 1998-08-20 | 2005-07-16 | Sumitomo Pharmaceuticals Company, Limited | Derivados de oxindol como liberadores de la hormona del crecimiento. |
| FR2827604B1 (fr) * | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| JPWO2005035498A1 (ja) * | 2003-10-08 | 2006-12-21 | 住友製薬株式会社 | 含窒素二環性化合物の摂食調節剤としての用途 |
-
2007
- 2007-08-16 FR FR0705858A patent/FR2920023B1/fr not_active Expired - Fee Related
-
2008
- 2008-08-14 BR BRPI0815171 patent/BRPI0815171A2/pt not_active Application Discontinuation
- 2008-08-14 PT PT08845678T patent/PT2188253E/pt unknown
- 2008-08-14 MY MYPI2010000685A patent/MY149649A/en unknown
- 2008-08-14 RS RS20120207A patent/RS52321B/sr unknown
- 2008-08-14 AT AT08845678T patent/ATE548349T1/de active
- 2008-08-14 PE PE2008001384A patent/PE20090988A1/es not_active Application Discontinuation
- 2008-08-14 AU AU2008320718A patent/AU2008320718B2/en not_active Ceased
- 2008-08-14 HR HRP20120466AT patent/HRP20120466T1/hr unknown
- 2008-08-14 WO PCT/FR2008/001190 patent/WO2009056707A2/fr not_active Ceased
- 2008-08-14 SI SI200830646T patent/SI2188253T1/sl unknown
- 2008-08-14 PL PL08845678T patent/PL2188253T3/pl unknown
- 2008-08-14 MX MX2010001851A patent/MX2010001851A/es active IP Right Grant
- 2008-08-14 UA UAA201002977A patent/UA101162C2/ru unknown
- 2008-08-14 EA EA201070281A patent/EA019486B1/ru not_active IP Right Cessation
- 2008-08-14 ES ES08845678T patent/ES2384080T3/es active Active
- 2008-08-14 PA PA20088793101A patent/PA8793101A1/es unknown
- 2008-08-14 CN CN200880103992.3A patent/CN103443076B/zh not_active Expired - Fee Related
- 2008-08-14 JP JP2010520610A patent/JP5685440B2/ja not_active Expired - Fee Related
- 2008-08-14 AR ARP080103547A patent/AR067937A1/es unknown
- 2008-08-14 ME MEP-2010-29A patent/ME00979B/me unknown
- 2008-08-14 KR KR1020107003267A patent/KR20100051812A/ko not_active Abandoned
- 2008-08-14 NZ NZ583317A patent/NZ583317A/en not_active IP Right Cessation
- 2008-08-14 CA CA2696237A patent/CA2696237C/fr active Active
- 2008-08-14 EP EP08845678A patent/EP2188253B8/fr active Active
- 2008-08-14 DK DK08845678.5T patent/DK2188253T3/da active
- 2008-08-14 JO JO2008376A patent/JO2749B1/en active
- 2008-08-15 UY UY31297A patent/UY31297A1/es not_active Application Discontinuation
- 2008-08-15 TW TW097131363A patent/TWI432423B/zh not_active IP Right Cessation
-
2010
- 2010-01-13 TN TNP2010000025A patent/TN2010000025A1/fr unknown
- 2010-02-03 NI NI201000023A patent/NI201000023A/es unknown
- 2010-02-04 DO DO2010000050A patent/DOP2010000050A/es unknown
- 2010-02-05 CO CO10012804A patent/CO6251363A2/es not_active Application Discontinuation
- 2010-02-09 US US12/702,687 patent/US20100210662A1/en not_active Abandoned
- 2010-02-10 GT GT201000032A patent/GT201000032A/es unknown
- 2010-02-12 CR CR11273A patent/CR11273A/es unknown
- 2010-02-12 EC EC2010009961A patent/ECSP109961A/es unknown
- 2010-02-14 IL IL203956A patent/IL203956A/en not_active IP Right Cessation
- 2010-02-15 ZA ZA2010/01085A patent/ZA201001085B/en unknown
- 2010-02-16 HN HN2010000330A patent/HN2010000330A/es unknown
- 2010-03-08 MA MA32676A patent/MA31742B1/fr unknown
-
2011
- 2011-01-24 US US13/012,321 patent/US8202871B2/en not_active Expired - Fee Related
-
2012
- 2012-05-30 CY CY20121100490T patent/CY1112809T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067937A1 (es) | Derivados de indol -2- ona disustituidos en 3, su preparacion y su aplicacion en terapeutica | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| AR064452A1 (es) | Derivados de 1,2,4 oxadiazol-indol,composiciones farmaceuticas que los comprenden y usos en trastornos asociados a receptores s1p1. | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| AR065322A1 (es) | 2-aminooxazolinas comoligandos de taar1 | |
| ES2668775T3 (es) | Compuestos tetracíclicos | |
| DK1856045T3 (da) | 1-eddikesyreindolderviater med PGD2-antagonisteffekt | |
| JP2008505194A5 (es) | ||
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| AR073369A1 (es) | Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3 | |
| AR072224A1 (es) | Derivados de pirimidona sustituidos | |
| AR078884A1 (es) | Antagonistas del receptor crth2 basados en indol | |
| AR064423A1 (es) | Derivados de dihidro-bencimidazol-2-ona y dihidro-indol-2-ona, una composicion farmaceutica que los comprende y su uso para el tratamiento de enfermedades mediadas por la modulacion de la serina palmitoiltransferasa. | |
| AR058077A1 (es) | Derivados de acidos fenoxiaceticos | |
| CR10034A (es) | Derivados de oxadiazol | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| AR056445A1 (es) | Derivados arilicos y heteroarilicos de 6 miembros para tratar virus | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR054797A1 (es) | Derivados de quinolina, composicion farmaceutica que lo comprende y su uso en la preparacion de un medicamento para el tratamiento de infecciones virales por virus de la familia flaviviridae, tal como hcv. | |
| AR073511A1 (es) | Derivados de isoquinolinona como antagonistas de nk3 | |
| AR056204A1 (es) | Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |